Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.61 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660186 | 0.86 | CYP3A4 (0.51) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL27717956 | 0.86 | CYP4F2 (0.62) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL3642367 | 0.85 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL757447 | 0.84 | LOXL2 (0.64) | CYP4F2CYP4A11MAPTNPC1RAB9A | |
| SCHEMBL20377195 | 0.84 | CA12 (0.53) | CYP4F2CYP4A11CA2NPC1KMT2A | |
| SCHEMBL129801 | 0.84 | CYP4F2 (0.71) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL129800 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL14415228 | 0.82 | SLC7A5 (0.59) | CYP4F2CYP4A11MAPTKMT2AMEN1 | |
| SCHEMBL5830966 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11MEP1BCA2MAPT | |
| SCHEMBL28813161 | 0.81 | MEN1 (0.48) | CYP4F2CYP4A11MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-110878012-A | Synthetic method of E-type methyl styrene compound | 南京大学 | 2020-03-13 | — | — | CN | disclosed |
| US-9078909-B2 | Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| EP-1819670-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1819670-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2265576-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | Allergan, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7732443-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. | 2010-06-08 | — | — | US | disclosed |
| US-7732443-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. | 2010-06-08 | — | — | US | disclosed |
| US-20090239869-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239869-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7427685-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427685-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| EP-1819670-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006063179-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | MCL1, GLI1, BID | CYP4F2 2975/4885CYP4A11 1716/4885MEP1B 3860/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | CYP4F2 1621/4885CYP4A11 266/4885MEP1B 421/4885 |
| US-20090239869-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | BBOX1, PDE6D, EYA3 | CYP4F2 2819/4885CYP4A11 241/4885MEP1B 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.